Please login to the form below
Crucell
This page shows the latest Crucell news and features for those working in and with pharma, biotech and healthcare.
Janssen’s quest to prevent diseases taking hold
Janssen’s acquisition of Crucell in 2011 brought it a suite of promising platforms covering HIV, a universal flu vaccine, respiratory syncytial virus (RSV), which is an infection of the lungs
Latest news
-
Ebola vaccine halt 'a precaution' say researchers
Meanwhile, Johnson &Johnson (J&J) is also stepping up production of its own candidate - being developed by subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National
-
J&J to produce one million doses of Ebola vaccine
The vaccine is being developed by J&J's Netherlands-based subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National Institutes of Health (NIH). ... It combines Crucell's AdVac technology and Bavarian Nordi's MVA-BN
-
J&J fast-tracks Ebola vaccine
The US-based healthcare giant's subsidiary Crucell – based in the Netherlands – is collaborating with the Danish biotech Bavarian Nordic on a combination vaccine regimen with clinical trials in humans planned ... So far the regimen – which combines
-
Janssen boosts vaccines pipeline with GlycoVaxyn deal
Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead
-
J&J complete acquisition of Crucell
As a result of the deal, Crucell will become the centre for vaccines within the J&J group. ... In October 2010, J&J reached an agreement with Crucell on its 24.75 a share purchase offer.
More from news
Approximately 1 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Kiadis Pharma appoints new chief operations officer
Prior to his time at Janssen, Feijen held positions for the likes of Crucell, Avebe and Gist Brocades.
-
Cell Medica adds to senior management team
He brings extensive experience in biotechnology manufacturing to the role, having held senior leadership positions at Crucell, Merck, Roche and Schering-Plough.
-
TiGenix appoints Dr Marie Paule Richard
She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... pharmacovigilance and medical affairs at Crucell in Switzerland.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Moderna to launch Innovation and Technology Center in the UK
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- VMLY&R wins two Grand Prix awards at Cannes Lions International Festival of Creativity 2022
- How digital health is changing the relationship between patients and health providers | OPEN Health
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Roche shares new positive Ocrevus data for MS patients
- Six UK universities receive grant for research into motor neurone disease
PMHub
Origins Insights
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
